Zobrazeno 1 - 10
of 79
pro vyhledávání: '"E Chamorro-De Vega"'
Autor:
M Ferris Villanueva, E Chamorro de Vega, CG Gonzalez Rodriguez, B Torroba Sanz, J Vicente Valor, A Herranz Alonso, M Sanjurjo Sáez
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b6e2f850c304d9b9e344a9241ad2ac6
https://doi.org/10.1136/ejhpharm-2023-eahp.316
https://doi.org/10.1136/ejhpharm-2023-eahp.316
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A Calvo García, V Escudero Vilaplana, E Ramirez Herraiz, B Hernandez Muniesa, M Fernández Pacheco Garcia-Valdecasas, R Romero Jiménez, E Chamorro De Vega, N Herrero Muñoz, B Ubeda Ruiz, A Morell Baladron
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2d2ab866de9ab83b04ce65389d34036
https://doi.org/10.1136/ejhpharm-2022-eahp.90
https://doi.org/10.1136/ejhpharm-2022-eahp.90
Autor:
C Villanueva Bueno, A Melgarejo Ortuño, B Somoza Fernandez, J Vicente Valor, FJ Garcia Moreno, C Rodriguez Gonzalez, E Chamorro de Vega, A. De Lorenzo Pinto, I Taladriz Sender, M Sanjurjo Sáez, A Herranz Alonso
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Identification of the angiotensin converting enzyme (ACE2) as a target of the SARS-CoV-2 virus raises questions about a possible change in the clinical course of this infection associated with inhibitors of the renin-angiote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cceb8070cd8df8ebb8b0e24f79115eae
https://doi.org/10.1136/ejhpharm-2021-eahpconf.253
https://doi.org/10.1136/ejhpharm-2021-eahpconf.253
Autor:
RM Romero Jiménez, ME Lobato Matilla, S García Sánchez, M Sanjurjo Sáez, Á Narrillos Moraza, A Herranz Alonso, A. Ais Larisgoitia, Alejandra Melgarejo-Ortuño, E Chamorro de Vega
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Patients with immune mediated inflammatory diseases (IMID) have complex treatment. This is due to biological treatments, other chronic treatments, such as immunosuppressors, and the high load of treatments. Aim and objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1505c56d60c5b683519f0bf928c2b5dc
https://doi.org/10.1136/ejhpharm-2021-eahpconf.161
https://doi.org/10.1136/ejhpharm-2021-eahpconf.161
Autor:
C Rodriguez Gonzalez, E Chamorro de Vega, J Vicente Valor, P Ruiz Briones, M Olmedo Samperio, B Somoza Fernandez, Pernia López, A Herranz Alonso, Á Narrillos Moraza, M Sanjurjo Sáez
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Oral vancomycin (125 mg four times daily) is the standard treatment for mild/moderate Clostridium difficile infection (CDI). As there are no marketed vancomycin capsules in our country, vancomycin 500 mg vials have been take
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::633d446e06ce18c5ef4457f276b86fac
https://doi.org/10.1136/ejhpharm-2021-eahpconf.70
https://doi.org/10.1136/ejhpharm-2021-eahpconf.70
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maria Luisa Martin-Barbero, Sara Ibáñez-García, María Sanjurjo-Sáez, Ana Herranz-Alonso, CG Rodriguez-Gonzalez, E Chamorro-De Vega, JL de la Rosa
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Clinical decision support systems (CDSS) can play an important role in facilitating antimicrobial stewardship programmes (ASP). However, the effects of CDSS in improving antimicrobial therapy have been insufficiently studied. Purpose To ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e7a73d3f72a4d94780536883938d88
https://doi.org/10.1136/ejhpharm-2019-eahpconf.466
https://doi.org/10.1136/ejhpharm-2019-eahpconf.466
Autor:
CG Rodriguez-Gonzalez, María Olmedo, Maricela Valerio, María Sanjurjo-Sáez, Ana Herranz-Alonso, E Chamorro-De Vega, ME Rochet, Patricia Muñoz
Publikováno v:
Section 6: Education and Research.
Background Dalbavancin (DAL) has recently been approved to treat complicated skin and soft tissue infections. It enables treatments with a single IV administration, so it is a highly attractive option in other infections that requires long-term treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db9ba76ac2bb94444d5fb305be11aaa1
https://doi.org/10.1136/ejhpharm-2019-eahpconf.604
https://doi.org/10.1136/ejhpharm-2019-eahpconf.604